Loading
Old version — revision 1
This is a fixed snapshot of Decellularized scaffolds, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/decellularized-scaffolds.md — the filesystem corpus, unchanged. Not an edit.
Donor tissues stripped of their cells to leave an extracellular matrix scaffold, used as surgical implants and as a route to rebuilding whole organs from a preserved vascular tree.
Decellularized scaffolds are tissues or whole organs from which the cells have been removed, leaving the extracellular matrix intact. The matrix retains the tissue's three-dimensional architecture, its mechanical properties, its basement membranes and, critically for organ work, its vascular tree. Acellular matrix products of this kind are routine in surgery. Whole decellularized organs, reseeded with a recipient's cells, are the most structurally complete approach anyone has to growing a replacement organ, and remain a rodent-scale result.
Decellularization removes cellular material without destroying the matrix that surrounds it — a balance, since every agent aggressive enough to lyse cells also degrades matrix components.
Ionic detergents such as sodium dodecyl sulfate strip cells efficiently but denature proteins and remove glycosaminoglycans and matrix-bound growth factors. Non-ionic detergents such as Triton X-100 are gentler and less complete. Most protocols combine them with enzymatic steps, usually a nuclease to digest residual DNA, and with physical treatments such as freeze-thaw cycling.
For thin tissues the agents are applied by immersion and agitation. For whole organs the decisive technique is perfusion decellularization: cannulating the organ's artery and pushing detergent through the native vasculature, so that every cell is reached through the same route that once supplied it with blood. This preserves the vascular architecture down to the capillary bed, which is the property no fabrication method can currently reproduce and the reason the approach persists despite its difficulties.
Adequacy is judged against quantitative criteria rather than appearance: no visible nuclear material on staining, residual double-stranded DNA below roughly fifty nanograms per milligram of dry tissue, and remaining fragments shorter than about two hundred base pairs.1 Residual DNA and residual detergent are both associated with inflammatory responses in the recipient.
An acellular matrix is not inert packing. It carries laminin and fibronectin binding sites that direct cell attachment, collagen architecture that sets stiffness and alignment, and sequestered growth factors released as the matrix is degraded. Stephen Badylak's work established that implanted matrix does not simply persist as a scaffold but is remodelled: it recruits host cells, degrades over weeks, and biases infiltrating macrophages toward a reparative rather than inflammatory phenotype, producing what he termed constructive remodelling. In a small clinical study, matrix implants placed into sites of traumatic volumetric muscle loss were associated with new muscle formation and functional improvement.2 The result is modest against the standard set by animals capable of true Limb regeneration, and it is the closest thing to induced structural regeneration achieved in human patients.
Digested matrix is also used as a culture substrate, replacing tumour-derived basement membrane gel in Organoids work and serving as a tissue-specific component of printable bioinks.
This immunological steering is now understood as central rather than incidental, and connects to the finding, established in mice rather than in patients, that scaffold-driven regeneration depends on type 2 immune signalling, discussed in Tissue engineering.
The commercially successful applications are all thin, load-bearing or barrier tissues where host cells can migrate in and vascularize the graft from the edges.
Acellular human dermal matrix is used in breast reconstruction, abdominal wall repair and burn care. Porcine small intestinal submucosa is used for hernia repair, wound care and soft tissue reinforcement. Decellularized human and porcine heart valves are implanted, particularly in children, where a valve that the recipient's cells can populate and that grows with the patient is worth a great deal. Decellularized nerve allografts are a standard option for bridging peripheral nerve gaps. Decellularized bone and tendon are widespread in orthopaedics.
None of these is a lab-grown organ. They are matrices that the patient's body converts into tissue, which is a lower bar and a more reliable one.
Each of the rodent results represented a genuine first and a small fraction of native function. The decellularized rat heart generated a fraction of the pressure of a working heart; the reseeded kidney produced urine far more dilute than a native one. Scaling to human organs multiplies the cell requirement roughly a thousandfold and lengthens every diffusion path. Supplying that many cells of the right types is itself a manufacturing problem, addressed in most current work by differentiating Induced pluripotent stem cells, and for the heart the practical alternative has remained the mechanical pump described in Artificial heart.
The specific barrier is the endothelium. A decellularized vascular tree presents bare collagen to blood, which is thrombogenic; unless the entire luminal surface is recoated with functional endothelial cells, the graft clots within hours of perfusion. The interaction of blood with an imperfect artificial surface is the same constraint that governs mechanical circulatory support and the oxygen carriers described in Artificial blood. Achieving complete re-endothelialization across the whole tree, including capillaries, has not been demonstrated at human scale. The practical response has been to lower the goal: rather than an implantable organ, an externally perfused humanized pig liver used as temporary support for liver failure, where blood contacts the device outside the body and anticoagulation is manageable.
The field's most damaging episode began with a decellularized scaffold and continued with synthetic ones. In 2008 Paolo Macchiarini's group reported implanting a decellularized donor trachea seeded with the recipient's own cells into a woman with end-stage airway disease, and described the result as a success.3 From 2011, at the Karolinska Institute, he implanted synthetic polymer tracheas seeded with bone marrow cells into patients including a young child. Most recipients died. There had been no adequate large-animal preclinical work, the interventions were justified as compassionate use in patients who were not all critically ill, and published follow-up overstated the outcomes.
Four Karolinska clinicians who raised concerns were investigated and reprimanded before the allegations were substantiated. An external inquiry found misconduct, Macchiarini was dismissed in 2016, and a 2011 paper describing the synthetic trachea was retracted in 2018. Swedish courts pursued criminal charges; an appeals court convicted him of gross assault in 2023 and imposed a prison sentence.
What the case actually showsThe failure was not that the technology was implausible in principle. It was procedural: no controls, no preclinical foundation, patient selection driven by the surgeon, institutional incentives favouring a celebrated recruit, and a compassionate-use pathway that permitted repeated first-in-human procedures without accumulating evidence. Any regenerative therapy can be run this way, and the safeguards that failed were not specific to tracheas. The structural resemblance to the death of Jesse Gelsinger, which set back Somatic gene therapy by years, and to the He Jiankui affair is close: in each case a researcher moved to humans ahead of the evidence, and institutional review either failed or was bypassed.
Beyond re-endothelialization, four constraints recur. Residual antigens in xenogeneic matrix, notably the alpha-gal epitope that also drives rejection in Xenotransplantation, provoke immune responses even after cells are removed. Detergent residues are cytotoxic and hard to wash out of dense matrix. Decellularization degrades mechanical strength, which matters for valves and vessels expected to last decades. And obtaining human donor organs to decellularize competes with using them directly, so the scalable version of the approach depends on animal organs, with the antigenicity that implies.
Regulators have responded to the trachea cases by tightening the compassionate-use route for engineered tissues, an instance of the Precautionary principle operating retrospectively: the restrictions arrived after the deaths rather than before them.
Decellularized matrix has an assured place as a surgical biomaterial and as a bioink component for Organ bioprinting. Its role in whole-organ replacement is less certain. The strongest argument for it is that the vascular tree is the hardest part of an organ to build and the easiest part to inherit; the strongest argument against is that nearly two decades after the rat heart, no group has recellularized a human-scale organ to a functional cell density.
The near-term test is whether externally perfused bioengineered organs work as bridging therapy in liver failure, which would validate the recellularization chemistry without requiring implantation. If that fails, the approach's contribution to the Organ shortage would be as a scaffold material rather than as an organ, leaving the supply problem to Lab-grown organs by other routes and to edited animals.
paperCrapo, P. M., Gilbert, T. W. and Badylak, S. F. "An overview of tissue and whole organ decellularization processes." Biomaterials, 2011.↩A review; the widely quoted residual-DNA thresholds originate here as proposed criteria rather than as values derived from clinical outcomes.
paperSicari, B. M. et al. "An acellular biologic scaffold promotes skeletal muscle formation in mice and humans." Science Translational Medicine, 2014.↩The human arm is a small open-label case series with no control group; the controlled comparisons in the paper are in mice.
paperMacchiarini, P. et al. "Clinical transplantation of a tissue-engineered airway." The Lancet, 2008.↩The paper that reported the first case as a success; its lead author was later found to have committed misconduct in the trachea programme that followed.